AU2001261832A1 - Methods for inhibiting proliferation and inducing apoptosis in cancer cells - Google Patents

Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Info

Publication number
AU2001261832A1
AU2001261832A1 AU2001261832A AU6183201A AU2001261832A1 AU 2001261832 A1 AU2001261832 A1 AU 2001261832A1 AU 2001261832 A AU2001261832 A AU 2001261832A AU 6183201 A AU6183201 A AU 6183201A AU 2001261832 A1 AU2001261832 A1 AU 2001261832A1
Authority
AU
Australia
Prior art keywords
leukotriene
alkyl
compound
ethyl
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261832A
Other languages
English (en)
Inventor
Thomas E. Adrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creighton University
Original Assignee
Creighton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creighton University filed Critical Creighton University
Publication of AU2001261832A1 publication Critical patent/AU2001261832A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001261832A 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells Abandoned AU2001261832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
US60219344 2000-05-09
PCT/US2001/040697 WO2001085166A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Publications (1)

Publication Number Publication Date
AU2001261832A1 true AU2001261832A1 (en) 2001-11-20

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261832A Abandoned AU2001261832A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Country Status (11)

Country Link
EP (1) EP1326605A4 (zh)
JP (1) JP2003532675A (zh)
KR (1) KR20030019372A (zh)
CN (1) CN1237968C (zh)
AU (1) AU2001261832A1 (zh)
BR (1) BR0110473A (zh)
CA (1) CA2408622A1 (zh)
MX (1) MXPA02010974A (zh)
NO (1) NO20025343L (zh)
NZ (1) NZ522387A (zh)
WO (1) WO2001085166A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (en) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
KR20140099546A (ko) 2012-01-10 2014-08-12 일라이 릴리 앤드 캄파니 류코트리엔 b4 길항제 화합물
WO2014175253A1 (ja) 2013-04-22 2014-10-30 株式会社栃木臨床病理研究所 抗腫瘍剤
MX2016008247A (es) 2013-12-20 2016-10-21 Novartis Ag Derivados de acido heteroaril butanoico como inhibidores de lta4h.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
US6235785B1 (en) * 1994-08-31 2001-05-22 Eli Lilly And Company Methods for identifying and treating resistant tumors
HUP9904672A2 (hu) * 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
MXPA02004733A (es) * 1999-11-11 2002-08-30 Lilly Co Eli Combinaciones oncoliticas para el tratamiento del cancer.
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU2041801A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Also Published As

Publication number Publication date
CN1237968C (zh) 2006-01-25
CA2408622A1 (en) 2001-11-15
JP2003532675A (ja) 2003-11-05
WO2001085166A1 (en) 2001-11-15
BR0110473A (pt) 2003-04-01
CN1429111A (zh) 2003-07-09
EP1326605A1 (en) 2003-07-16
EP1326605A4 (en) 2004-03-17
NO20025343L (no) 2003-01-09
KR20030019372A (ko) 2003-03-06
MXPA02010974A (es) 2004-09-06
NO20025343D0 (no) 2002-11-07
NZ522387A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
Pizer et al. Increased fatty acid synthase as a therapeutic target in androgen‐independent prostate cancer progression
Masferrer et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
Orita et al. Selective inhibition of fatty acid synthase for lung cancer treatment
Stuckler et al. RLIP76 Transports Vinorelbine and Mediates Drug Resistance in Non–Small Cell Lung Cancer
RU2389507C2 (ru) Лечение рака
US10420814B2 (en) Composition for treating cancer stem cells
KR102361078B1 (ko) 말산-아스파르트산 왕복수송 억제제 및 카르니틴 아실카르니틴 운반자 수송 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
US11046647B2 (en) Activators of the unfolded protein response
JP2003513920A (ja) 細胞内マロニルＣｏＡレベルの増加による癌の治療
Gu et al. Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation
TW201609094A (zh) 治療癌症之新穎方法
US7749962B2 (en) Alpha 5 beta 1 and its ability to regulate the cell survival pathway
AU2001261832A1 (en) Methods for inhibiting proliferation and inducing apoptosis in cancer cells
Tada et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma
US20040053962A1 (en) Methods for inhibiting proliferation and inducing apoptosis in cancer cells
JPWO2008139952A1 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
US6054437A (en) Method for inducing death of neoplastic cells using piperazine derivatives
US9895363B2 (en) Methods for modulating function of proliferating cell nuclear antigen (PCNA) and treating cancer with PCNA-targeting compounds
Liu et al. A novel small molecular STAT3 inhibitor, 5Br-6b, induces apoptosis and inhibits migration in colorectal cancer cells
WO2019098288A1 (ja) 抗腫瘍剤及び配合剤
JP2021127292A (ja) Ｍｅｆ２ｄ融合型急性リンパ性白血病の治療方法及び治療剤
CN102847155B (zh) 抑制肿瘤转移的方法
CA2436536C (en) Methods for inducing apoptosis and inhibiting proliferation in cancer cells
WO2017103625A1 (en) Cancer treatment
JP2005247807A (ja) Ｎｓａｉｄを利用した癌治療用組成物

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application